Next Generation Complement Therapeutics Market Size is valued at USD 5,070.9 Mn in 2024 and is predicted to reach USD 12,983.6 Mn by the year 2034 at a 10.0% CAGR during the forecast period for 2025-2034.
Next-generation complement therapeutics are advanced pharmaceutical interventions designed to modulate the complement system more precisely, effectively, and safer than earlier therapies. These therapeutics target specific complement proteins (e.g., C3, C5, C5a, factor D) or pathways to treat rare and chronic diseases driven by dysregulated complement activation. These therapies introduce novel targets (e.g., C3, factor B, factor D), modalities (e.g., peptides, small molecules, aptamers), or improved pharmacokinetics (e.g., longer half-life). The complement system is vital in pathogen immunosurveillance, and complement activation is a part of numerous inflammatory diseases. Hence, several pharma companies started focusing on discovering next-generation complement therapeutics to treat different disease conditions.
Major driving factors of the next-generation complement therapeutics market are rising government efforts to develop complement-targeted therapeutics, advancements in technologies, increasing investments by pharma companies to innovate next-generation complement therapeutics products, growing patient population, increasing R&D activities in complement therapeutics, growing prevalence of chronic diseases, and the high need for novel therapeutics to manage normal immune system functioning. Various drug developers prefer adopting next-generation technologies to develop complement-targeted therapeutics for effectively treating immunodeficiency disorders. This adoption is predicted to compel market growth in the upcoming years. However, a large population living with complement deficiency remains undiagnosed, hindering the market growth during the estimated timeframe.
The next-generation complement therapeutics market is segmented into indication, therapeutic area, molecule type, complement inhibition, therapy type, route of administration. By Product, the market is divided into Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy secondary to Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Others. Whereas, as per the Therapeutic Area, the market includes Hematology, Ophthalmology, Neurology, Immunology/Rheumatology, Other. The Molecule Type segment comprises Biologic, Small Molecule. The Complement Inhibition segment is classified into C5 Inhibitor, C3 Inhibitor, Other Targets. According to the Route of Administration, the market is further divided into Intravenous, Oral, Intravitreal, Subcutaneous. The Therapy Type segment includes Monotherapy, and Adjunctive Therapy.
North America dominated this market in 2024. The presence of a well-established healthcare infrastructure, advantageous reimbursement policies, collaborative partnerships, the introduction of new products, and notable pharmaceutical companies involved in Complement Inhibitors are all contributing factors. Moreover, The Asia-Pacific market is projected to notice substantial growth during the forecast period due to the rising research activities in the complement therapeutics, well-developed healthcare infrastructure and increasing patient pool.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 5,070.9 Mn |
|
Revenue Forecast In 2034 |
USD 12,983.6 Mn |
|
Growth Rate CAGR |
CAGR of 10.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Indication, Therapeutic Area, Molecule Type, Complement Inhibition, Therapy Type, Route Of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Apellis Pharmaceuticals, Inc., AstraZeneca, ChemoCentryx/Amgen, Iveric Bio/Astellas Company, UCB, Regeneron, Novartis, Roche, ImmunAbs Inc., Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next Generation Complement Therapeutics Market Snapshot
Chapter 4. Global Next Generation Complement Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Porter's Five Forces Analysis
4.6. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.7. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.8. Use/impact of AI on Next Generation Complement Therapeutics Market Industry Trends
4.9. Global Next Generation Complement Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Next Generation Complement Therapeutics Market Segmentation 1: By Indication, Estimates & Trend Analysis
5.1. Market Share by Indication, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
5.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
5.2.2. Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD)
5.2.3. Generalized Myasthenia Gravis (gMG)
5.2.4. Atypical Hemolytic Uremic Syndrome (aHUS)
5.2.5. Others
Chapter 6. Next Generation Complement Therapeutics Market Segmentation 2: By Therapeutic Area, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Area, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Area:
6.2.1. Hematology
6.2.2. Ophthalmology
6.2.3. Neurology
6.2.4. Immunology/Rheumatology
6.2.5. Other
Chapter 7. Next Generation Complement Therapeutics Market Segmentation 3: By Molecule Type, Estimates & Trend Analysis
7.1. Market Share by Molecule Type, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:
7.2.1. Biologic
7.2.2. Small Molecule
Chapter 8. Next Generation Complement Therapeutics Market Segmentation 4: By Complement Inhibition, Estimates & Trend Analysis
8.1. Market Share by Complement Inhibition, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Complement Inhibition:
8.2.1. C5 Inhibitor
8.2.2. C3 Inhibitor
8.2.3. Other
Chapter 9. Next Generation Complement Therapeutics Market Segmentation 4: By Route of Administration Inhibition, Estimates & Trend Analysis
9.1. Market Share by Route of Administration, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
9.2.1. Intravenous
9.2.2. Oral
9.2.3. Intravitreal
9.2.4. Subcutaneous
Chapter 10. Next Generation Complement Therapeutics Market Segmentation 4: By Therapy Type, Estimates & Trend Analysis
10.1. Market Share by Therapy Type, 2024 & 2034
10.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type:
10.2.1. Monotherapy
10.2.2. Adjunctive Therapy
Chapter 11. Next Generation Complement Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
11.1. Global Next Generation Complement Therapeutics Market, Regional Snapshot 2024 & 2034
11.2. North America
11.2.1. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.2.1.1. US
11.2.1.2. Canada
11.2.2. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.2.3. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.2.4. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.2.5. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.2.6. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.2.7. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.3. Europe
11.3.1. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. Rest of Europe
11.3.2. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.3.3. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.3.4. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.3.5. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.3.6. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.3.7. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.4. Asia Pacific
11.4.1. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.4.1.1. India
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific
11.4.2. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.4.3. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.4.4. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.4.5. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.4.6. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.4.7. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.5. Rest of the world
11.5.1. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Rest of the world
11.5.2. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.5.3. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.5.4. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.5.5. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.5.6. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.5.7. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Apellis Pharmaceuticals, Inc.
12.2.1.1. Business Overview
12.2.1.2. Key Indication/Service Overview
12.2.1.3. Financial Performance
12.2.1.4. Geographical Presence
12.2.1.5. Recent Developments with Business Strategy
12.2.2. AstraZeneca
12.2.3. ChemoCentryx/Amgen
12.2.4. Iveric Bio/Astellas Company
12.2.5. UCB
12.2.6. Regeneron
12.2.7. Novartis
12.2.8. Genentech/Roche
12.2.9. ImmunAbs Inc.
12.2.10. Other Prominent Players
Global Next-Generation Complement Therapeutics Market, by Indication, (Value US$ Mn)
Global Next-Generation Complement Therapeutics Market, by Therapeutic Area, (Value US$ Mn)
Global Next-Generation Complement Therapeutics Market, by Molecule Type, (Value US$ Mn)
Global Next-Generation Complement Therapeutics Market, by Route of Administration, (Value US$ Mn)
Global Next-Generation Complement Therapeutics Market, by Complement Inhibition, (Value US$ Mn)
Global Next-Generation Complement Therapeutics Market, by Type of Therapy, (Value US$ Mn)
Global Next-Generation Complement Therapeutics Market, by Region, (Value US$ Mn)
North America Next-Generation Complement Therapeutics Market, by Country, (Value US$ Mn)
Europe Next-Generation Complement Therapeutics Market, by Country, (Value US$ Mn)
Asia Pacific Next-Generation Complement Therapeutics Market, by Country, (Value US$ Mn)
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
